Research / Notes
Short-form hypotheses, research questions, thought experiments and things we still do not know. Every entry is dated, versioned and open to revision or withdrawal.
The same number of local faults may produce different functional outcomes when those faults are confined, randomly dispersed or arranged so that every reserve module shares the same failure mode.
This remains untested as a general aging principle. COV‑AGE is designed to reject it if geometry adds no effect beyond burden.
Derived from Breakthrough Process v2.0, sections 1, 3 and 12.
An on-treatment molecular change may reflect temporary pathway forcing. Durable function, recovery and a second challenge after the intervention ends are stronger early tests of whether a biological state actually changed.
Post-washout function is not a validated lifespan surrogate. It is a proposed research gate.
Derived from Adaptive Longevity Therapy v1.0 and Breakthrough Process v2.0.
Any intervention that changes growth, niche access, immune selection or tissue resources also changes the fitness landscape for pre-existing clones. Functional gain and cancer defence must therefore be optimised together from the first experiment.
This principle does not validate any screening test or intervention for an individual person.
Derived from Breakthrough Process v2.0, sections 8, 10 and 14.
Open questions
Can error covariance be manipulated independently of mean biological burden?
Will two defensible covariance definitions produce the same directional result?
Does a change in propagation precede a durable change in function?
Can a pattern effect reproduce across both cell-state and niche faults?
Can any benefit survive adversarial clone, infection and wound-repair testing?